PROSPECTIVE STUDY ON IMPROVING NIGHT'S REST AND QUALITY OF LIFE BY USING BOTULINUM TOXIN AT A DOSE OF 25 IU IN HEAD AND FACE PATHOLOGIES REFRACTORY TO ORAL TREATMENT. ON 283 CASES
Main Article Content
Abstract
The use of Botulinum Toxin is increasingly being extended in different conditions refractory to other treatments.
Thus, it is being used in dystonias, trigeminal neuralgia, migraines, headaches and alterations of the temporomandibular joint.
OBJECTIVES
Primary: To assess the improvement of night rest in the treatment with botulinum toxin type A in chronic Migraine. Trigeminal neuralgia (regardless of the affected branch) and involvement of the temporomandibular joint and/or Bruxism, after therapeutic failure maintained over time. Over more than two years of previous oral or topical drug therapies.
Secondary: To assess the effectiveness of the dose used and its average duration over time.
METHODS: 283 patients of both sexes, aged between 85 and 43 years, were included. The patients studied were separated by sex. Group A: over 80 years old. Group B: between 65 and 79 years old and Group C: under 64 years old.
25 IU of botulinum toxin type A were administered for trigeminal neuralgia, severe temporomandibular joint (TMJ) pain, migraines and headaches. , refractory for two years or more to medical treatments
RESULTS: In all groups, with doses of 25 IU in a single dose, there was a significant improvement in the rest, from the injection, until the six months of control, especially in the group C, in trigeminal neuralgia. It was not significant in the other conditions and/or age groups
CONCLUSIONS: In all groups the effectiveness was greater in trigeminal neuralgia at the established doses P<0.5 and more in the lower group age (C) with more than 6 months of improvement in the condition. In the rest of the pathologies treated, the results at the established doses are very similar to those of the referenced studies. Its use can be effective at doses of 25 IU.
Keywords:
Temporomandibular joint, trigeminal neuralgia, headaches, migraines. Botulinum toxin. Sleep.
Article Details
How to Cite
PALACÍN, Sistac; SALAS J, Viñas; BALLARIN, Sistac.
PROSPECTIVE STUDY ON IMPROVING NIGHT'S REST AND QUALITY OF LIFE BY USING BOTULINUM TOXIN AT A DOSE OF 25 IU IN HEAD AND FACE PATHOLOGIES REFRACTORY TO ORAL TREATMENT. ON 283 CASES.
Medical Research Archives, [S.l.], v. 13, n. 2, feb. 2025.
ISSN 2375-1924.
Available at: <https://esmed.org/MRA/mra/article/view/6228>. Date accessed: 17 mar. 2025.
doi: https://doi.org/10.18103/mra.v13i2.6228.
Section
Research Articles
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
1. Burgen, A.S.V.; Dickens, F.; Zatman, L.J. The action of botulinum toxin on the neuro-muscular junction. J. Physiol. (Lond.) 1949, 109, 10–24
2. Small RBotulinum toxin injection for facial wrinkles.Am Fam Physicia. 2014. 1;90(3):168-75.
3. DresslerD.Botulinum toxin drugs: brief history and outlook J Neural Transm. 2016;123(3): 277-9.doi: 10.1007/s00702-015-1478-1. Epub 2015 Nov 11.
4. Matak I, Bölcskei K, Bach-Rojecky L, Helyes Z. Mechanisms of Botulinum Toxin Type A Action on Pain. Toxins (Basel). 2019 Aug 5;11(8):459. doi: 10.3390/toxins11080459. PMID: 31387301; PMCID: PMC6723487.
5. Yasaman Safarpour 1, Bahman Jabbari 2 Botulinum toxin treatment of pain syndromes -an evidence based review. 2018;147:120-128. doi:10.1016/j.toxicon.2018.01.017.Epub 2018 Feb 1.
6. Jihye Park 1, Myung Eun Chung 2 Botulinum Toxin for Central Neuropathic Pain. Toxins. 2018; 10(6):224.-30 doi: 10.3390/toxins10060224.
7. Soza S. Cortés Monroy C. Usos prácticos de la toxina botulínica en adultos en medicina física y Rehabilitación REV. MED. CLIN. CONDES - 2014; 25(2) 225-236.
8. Ledermann W. D. Historia del Clostridium botulin Rev Chil Infect Edición aniversario 2003; 39-41
9. Benecke R. Relevancia clínica de la inmunogenicidad de la toxina botulínica. BioDrugs. 2012 Abr 1;26(2):e1-9. doi: 10.2165/11599840-000 000000-00000. PMID: 22385408; PMCID: PMC368 3397.
10. Matak I, Bölcskei K, Bach-Rojecky L, Helyes Z. Mechanisms of Botulinum Toxin Type A Action on Pain. Toxins (Basel). 2019 Aug 5;11(8):459. doi: 10.3390/toxins11080459. PMID: 31387301; PMCID: PMC6723487
11. Nixdorf DR, Heo GB, Major PW. Nixdorf DR, Heo GB, Major PW. Randomized controlled trial of botulinum toxin A for chronic myogenous orofacial pain. Pain. 2002;99:465–73.
12. Song PC, Schwartz J, Blitzer A. The emerging role of botulinum toxin in the treatment of temporomandibular disorders. Oral Dis. 2007;13: 253–60.
13. Nixdorf DR, Heo GB, Major PW. Randomized controlled trial of botulinum toxin A for chronic myogenous orofacial pain. Pain. 2002;99:465–73.
14. Ernberg M, Hedenberg-Magnusson B, List T, Svensson P. Efficacy of botulinum toxin type A for treatment of persistent myofascial TMD pain: A randomized, controlled, double-blind multicenter study. Pain. 2011;152:1988–96.
15. Guarda-Nardini L, Manfredini D, Salamone M, Salmaso L, Tonello S, Ferronato G. Efficacy of botulinum toxin in treating myofascial pain in bruxers: A controlled placebo pilot study. Cranio. 2008;26: 126–35
16. Micheli F, Scorticati MC, Raina G. Beneficial effects of botulinum toxin type a for patients with painful tic convulsif. Clin Neuropharmacol 2002; 25(5):260-2.
17. Rubis A, Juodzbalys G. The Use of Botulinum Toxin A in the Management of Trigeminal Neuralgia: a Systematic Literature Review. J Oral Maxillofac Res. 2020 Jun 30;11(2):e2. doi: 10.5037/jomr.2020.1 1202. PMID: 32760475; PMCID: PMC7393930.
18. Serrera-Figallo MA, Ruiz-de-León-Hernández G, Torres-Lagares D, Castro-Araya A, Torres-Ferrerosa O, Hernández-Pacheco E, Gutierrez-Perez JL. Use of Botulinum Toxin in Orofacial Clinical Practice. Toxins (Basel). 2020 Feb 11;12(2):112. doi: 10.339 0/toxins12020112. PMID: 32053883; PMCID: PMC7076767
19. WU Wu S, Lian Y, Zhang H, Chen Y, Wu C, Li S, Zheng Y, Wang Y, Cheng W, Huang Z. Botulinum Toxin Type A for refractory trigeminal neuralgia in older patients: a better therapeutic effect. J Pain Res. 2019;12:2177-2186. doi: 10.2147/JPR.S205467. PMID: 31410051; PMCID: MC6643497
20. Muñoz Lora VRM, Del Bel Cury AA, Jabbari B, Lacković Z. Botulinum Toxin Type A in Dental Medicine. J Dent Res. 2019;98(13):1450-1457. doi: 10.1177/0022034519875053. Epub 2019 Sep 18. PMID: 31533008
21. Moore D, Chong MS, Shetty A, Zakrzewska JM. A systematic review of rescue analgesic strategies in acute exacerbations of primary trigeminal neuralgia. Br J Anaesth. 2019 Aug;123(2):e385-e396. doi: 10.1016/j.bja.2019.05.026. Epub 2019 Jun 15. PMID: 31208761; PMCID: PMC6676170.
22. Sridharan K, Sivaramakrishnan G. Botulinum Toxin for Refractory Trigeminal Neuralgia: A Trial Sequential Analysis of Randomized Clinical Trials. J Neurosci Rural Pract.;9(1):3-4. doi: 10.4103/jnrp.jnr p_447_17. PMID: 29456335; PMCID: PMC5812155
23. Meng F, Peng K, Yang JP, Ji FH, Xia F, Meng XW. Botulinum toxin-A for the treatment of neuralgia: a systematic review and meta-analysis. J Pain Res. 2018 Oct 12;11:2343-2351. doi: 10.2147/ JPR.S168650. PMID: 30349359; PMCID: PMC6190 814
24. Castillo-Álvarez F, Hernando de la Bárcena I, Marzo-Sola ME. Botulinum toxin in trigeminal neuralgia. Med Clin. 2017;148(1):28-32. English, Spanish. doi: 10.1016/j.medcli.2016.07.032. Epub 2016 Oct 12. PMID: 27743594.
25. TURK Türk Börü Ü, Duman A, Bölük C, Coşkun Duman S, Taşdemir M. Botulinum toxin in the treatment of trigeminal neuralgia: 6-Month follow-up. Medicine (Baltimore). 2017;96(39):e8133. doi: 10.1097/MD.0000000000008133. PMID: 2895 3646; PMCID: PMC5626289.
26. Morra ME, Elgebaly A, Elmaraezy A, Khalil AM, Altibi AM, Vu TL, Mostafa MR, Huy NT, Hirayama K. Therapeutic efficacy and safety of Botulinum Toxin A Therapy in Trigeminal Neuralgia: a systematic review and meta-analysis of randomized controlled trials. J Headache Pain. 2016;17(1):63. doi: 10.118 6/s10194-016-0651-8. Epub 2016 Jul 5. PMID: 273 77706; PMCID: PMC4932020.
27. Oh HM, Chung ME. Botulinum Toxin for Neuropathic Pain: A Review of the Literature. Toxins (Basel). 2015;7(8):3127-54. doi: 10.3390/tox ins7083127. PMID: 26287242; PMCID: PMC4549742.
28. Hu Y, Guan X, Fan L, Li M, Liao Y, Nie Z, Jin L. Therapeutic efficacy and safety of botulinum toxin type A in trigeminal neuralgia: a systematic review. J Headache Pain. 2013;14(1):72. doi: 10.11 86/1129-2377-14-72. PMID: 23964790; PMCID: PMC3765392
29. Kaya DI, Ataoglu H. Botulinum toxin treatment of temporomandibular joint pain in patients with bruxism: A prospective and randomized clinical study. Niger J Clin Pract. 2021;24(3):412-417.
doi: 10.4103/njcp.njcp_251_20. PMID: 33723117.
30. La Fleur P, Adams A. Botulinum Toxin for Temporomandibular Disorders: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020 Feb 25. PMID: 33074614
31. Shandilya S, Mohanty S, Sharma P, Chaudhary Z, Kohli S, Kumar RD. Effect of Preoperative Intramuscular Injection of Botulinum Toxin A on Pain and Mouth Opening After Surgical Intervention in Temporomandibular Joint Ankylosis Cases: A Controlled Clinical Trial. J Oral Maxillofac Surg;78 (6):916-926. doi: 10.1016/j.joms.2020.02.011. Epub 2020 Feb 19. PMID: 32171600.
32. Thambar S, Kulkarni S, Armstrong S, Nikolarakos D. Botulinum toxin in the management of temporomandibular disorders: a systematic review. Br J Oral Maxillofac Surg. 2020;58(5):508-519. doi: 10.1016/j.bjoms.2020.02.007. Epub 2020 Mar 3. PMID: 32143934.
33. Machado D, Martimbianco ALC, Bussadori SK, Pacheco RL, Riera R, Santos EM. Botulinum Toxin Type A for Painful Temporomandibular Disorders: Systematic Review and Meta-Analysis. J Pain. 2020;21(3-4):281-293. doi: 10.1016/j.jpain.2 019.08.011. Epub 2019 Sep 9. PMID: 31513934.
34. Awan KH, Patil S, Alamir AWH, Maddur N, Arakeri G, Carrozzo M, Brennan PA. Botulinum toxin in the management of myofascial pain associated with temporomandibular dysfunction. J Oral Pathol Med.2019;48(3):192-200. doi: 10.1111/jop.12822. Epub 2019 Jan 25. PMID: 30604895.
35. Ghavimi MA, Yazdani J, Afzalimehr A, Ghoreyshizadeh A, Dehnad SV. Effect of injection of botulinum toxin on decreasing the symptoms and signs of masticatory muscles in patients with temporomandibular dysfunction. J Dent Res Dent Clin Dent Prospects. 2019 Spring;13(2):128-132. doi: 10.15171/joddd.2019.020. Epub 2019 Aug 14. PMID: 31592308; PMCID: PMC6773914
36. De la Torre Canales G, Câmara-Souza MB, do Amaral CF, Garcia RC, Manfredini D. Is there enough evidence to use botulinum toxin injections for bruxism management? A systematic literature review. Clin Oral Investig. 2017;21(3):727-734. doi: 10.1007/s00784-017-2092-4. Epub 2017 Mar 2. PMID: 28255752.
37. Thomas NJ, Aronovich S. Does Adjunctive Botulinum Toxin A Reduce Pain Scores When Combined With Temporomandibular Joint Arthroscopy for the Treatment of Concomitant Temporomandibular Joint Arthralgia and Myofascial Pain? J Oral Maxillofac Surg. 2017;75(12):2521-2528. doi: 10.1016/j.joms.2017.04.011. Epub 2017 Apr 19. PMID: 28500876.
38. Torres-Ferrus M, Gallardo VJ, Alpuente A, Pozo-Rosich P. Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA. J Headache Pain. 2020;21(1):88. doi: 10.1186/s101 94-020-01157-8. PMID: 32652924; PMCID: PMC7353810.
39. Bellon G, Venturin A, Masiero S, Del Felice A. Intra-articular botulinum toxin injection in complex regional pain syndrome: Case report and review of the literature. Toxicon. 2019;159:41-44. doi: 10.10 16/j.toxicon.2019.01.002. Epub 2019 Jan 17. PMID: 30660558.
40. Agostoni EC,Barbanti P, Calabresi P, Colombo B, Cortelli P, Frediani F, Geppetti P, Grazzi L, Leone M, Martelletti P, Pini LA, Prudenzano MP, Sarchielli P, Tedeschi G, Russo A; Italian chronic migraine group. Current and emerging evidence-based treatment options in chronic migraine: a narrative review. J Headache Pain. 2019;20(1):92. doi: 10.1186/s10194-019-1038-4. PMID: 31470791; PMCID: PMC6734211.
41. Kelli. AM. The minimum clinically significant difference in visual analogue scale pain score does not differ with severity of pain. Emerg Med J 2001; 18:205–7. 10.1136/emj.18.3.205.
42. Luvisetto S. Botulinum Toxin and Neuronal Regeneration after Traumatic Injury of Central and Peripheral Nervous System. Toxins (Basel). 2020;12 (7):434. doi: 10.3390/toxins12070434. PMID: 3263 0737; PMCID: PMC7404966
43. Herd CP, Tomlinson CL, Rick C, Scotton WJ, Edwards J, Ives NJ, Clarke CE, Sinclair AJ. Cochrane systematic review and meta-analysis of botulinum toxin for the prevention of migraine. BMJ Open. 2019;9(7):e027953. doi: 10.1136/bmjopen-2018-027953. PMID: 31315864; PMCID: PMC6661 560.
44. Herd CP, Tomlinson CL, Rick C, Scotton WJ, Edwards J, Ives NJ, Clarke CE, Sinclair AJ. Cochrane systematic review and meta-analysis of botulinum toxin for the prevention of migraine. BMJ Open. 2019;9(7):e027953. doi: 10.1136/bmjopen-2018-027953. PMID: 31315864; PMCID: PMC6661 560.
45. Freund B, Rao A. Efficacy of Botulinum Toxin in Tension-Type Headaches: A Systematic Review of the Literature. Pain Pract. 2019;19(5):541-551. doi: 10.1111/papr.12773. Epub 2019 Apr 22. PMID: 30742360.
46. Barad M, Sturgeon JA, Fish S, Dexter F, Mackey S, Flood PD. Response to BotulinumtoxinA in a migraine cohort with multiple comorbidities and widespread pain. Reg Anesth Pain Med. 2019; 44(6):660-668. doi: 10.1136/rapm-2018-100196. PMID: 31101743.
47. Mimeh H, Fenech Magrin AM, Myers S, Ghanem AM. A Critical Review of Botulinum Toxin Type A in the Prophylactic Treatment of Chronic Migraine in Adults. Aesthet Surg J. 2019;39(8):898-907. doi: 10.1093/asj/sjy224. PMID: 30184084.
48. Alpuente A, Gallardo VJ, Torres-Ferrus M, Alvarez-Sabin J, Pozo-Rosich P. Early efficacy and late gain in chronic and high-frequency episodic migraine with onabotulinumtoxinA. Eur J Neurol. 2019;26(12):1464-1470. doi: 10.1111/ene.14028. Epub 2019 Jul 18. PMID: 31220392.
49. Winner PK, Blumenfeld AM, Eross EJ, Orejudos AC, Mirjah DL, Adams AM, Brin MF. Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: Results of the COMPEL Study. Drug Saf. 2019;42(8):1013-1024. doi: 10.1007/s40264-019-00824-3. PMID: 31102144
50. Castrillo Sanz A, Morollón Sánchez-Mateos N, Simonet Hernández C, Fernández Rodríguez B, Cerdán Santacruz D, Mendoza Rodríguez A, Rodríguez Sanz MF, Tabernero García C, Guerrero Becerra P, Ferrero Ros M, Duate García-Luis J. Experience with botulinum toxin in chronic migraine. Neurologia. 2018;33(8):499-504. English.
51. Blumenfeld AM, Stark RJ, Freeman MC, Orejudos A, Manack Adams A. Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19(1):13. doi: 10.1186/s10194-018-0840-8. PMID: 29404713; PMCID: PMC5799088
52. Erdemoglu AK, Varlibas A. The long-term efficacy and safety of botulinum toxin in refractory chronic tension-type headache. J Headache Pain. 2007 Oct;8(5):294-300. doi: 10.1007/s10194-007-0414-7. Epub 2007 Oct 23. PMID: 17955170; PMCID: PMC3476152.
53. Mathew NT, Jaffri SF. A double-blind comparison of onabotulinumtoxina (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study. Headache 2009;49:1466–78. 10.1111/j.1526-4610.2009.01566.x
54. Venancio Rde A, Alencar FG Jr, Zamperini C. Botulinum toxin, lidocaine, and dry-needling injections in patients with myofascial pain and headaches. Cranio. 2009 Jan;27(1):46-53. doi: 10.1179/crn.2009.008. PMID: 19241799.
55. Jackson JL, Kuriyama A, Hayashino Y. Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis. JAMA. 2012; 307(16):1736-45. doi: 10.1001/jama.2012.505. PMID: 22535858.
2. Small RBotulinum toxin injection for facial wrinkles.Am Fam Physicia. 2014. 1;90(3):168-75.
3. DresslerD.Botulinum toxin drugs: brief history and outlook J Neural Transm. 2016;123(3): 277-9.doi: 10.1007/s00702-015-1478-1. Epub 2015 Nov 11.
4. Matak I, Bölcskei K, Bach-Rojecky L, Helyes Z. Mechanisms of Botulinum Toxin Type A Action on Pain. Toxins (Basel). 2019 Aug 5;11(8):459. doi: 10.3390/toxins11080459. PMID: 31387301; PMCID: PMC6723487.
5. Yasaman Safarpour 1, Bahman Jabbari 2 Botulinum toxin treatment of pain syndromes -an evidence based review. 2018;147:120-128. doi:10.1016/j.toxicon.2018.01.017.Epub 2018 Feb 1.
6. Jihye Park 1, Myung Eun Chung 2 Botulinum Toxin for Central Neuropathic Pain. Toxins. 2018; 10(6):224.-30 doi: 10.3390/toxins10060224.
7. Soza S. Cortés Monroy C. Usos prácticos de la toxina botulínica en adultos en medicina física y Rehabilitación REV. MED. CLIN. CONDES - 2014; 25(2) 225-236.
8. Ledermann W. D. Historia del Clostridium botulin Rev Chil Infect Edición aniversario 2003; 39-41
9. Benecke R. Relevancia clínica de la inmunogenicidad de la toxina botulínica. BioDrugs. 2012 Abr 1;26(2):e1-9. doi: 10.2165/11599840-000 000000-00000. PMID: 22385408; PMCID: PMC368 3397.
10. Matak I, Bölcskei K, Bach-Rojecky L, Helyes Z. Mechanisms of Botulinum Toxin Type A Action on Pain. Toxins (Basel). 2019 Aug 5;11(8):459. doi: 10.3390/toxins11080459. PMID: 31387301; PMCID: PMC6723487
11. Nixdorf DR, Heo GB, Major PW. Nixdorf DR, Heo GB, Major PW. Randomized controlled trial of botulinum toxin A for chronic myogenous orofacial pain. Pain. 2002;99:465–73.
12. Song PC, Schwartz J, Blitzer A. The emerging role of botulinum toxin in the treatment of temporomandibular disorders. Oral Dis. 2007;13: 253–60.
13. Nixdorf DR, Heo GB, Major PW. Randomized controlled trial of botulinum toxin A for chronic myogenous orofacial pain. Pain. 2002;99:465–73.
14. Ernberg M, Hedenberg-Magnusson B, List T, Svensson P. Efficacy of botulinum toxin type A for treatment of persistent myofascial TMD pain: A randomized, controlled, double-blind multicenter study. Pain. 2011;152:1988–96.
15. Guarda-Nardini L, Manfredini D, Salamone M, Salmaso L, Tonello S, Ferronato G. Efficacy of botulinum toxin in treating myofascial pain in bruxers: A controlled placebo pilot study. Cranio. 2008;26: 126–35
16. Micheli F, Scorticati MC, Raina G. Beneficial effects of botulinum toxin type a for patients with painful tic convulsif. Clin Neuropharmacol 2002; 25(5):260-2.
17. Rubis A, Juodzbalys G. The Use of Botulinum Toxin A in the Management of Trigeminal Neuralgia: a Systematic Literature Review. J Oral Maxillofac Res. 2020 Jun 30;11(2):e2. doi: 10.5037/jomr.2020.1 1202. PMID: 32760475; PMCID: PMC7393930.
18. Serrera-Figallo MA, Ruiz-de-León-Hernández G, Torres-Lagares D, Castro-Araya A, Torres-Ferrerosa O, Hernández-Pacheco E, Gutierrez-Perez JL. Use of Botulinum Toxin in Orofacial Clinical Practice. Toxins (Basel). 2020 Feb 11;12(2):112. doi: 10.339 0/toxins12020112. PMID: 32053883; PMCID: PMC7076767
19. WU Wu S, Lian Y, Zhang H, Chen Y, Wu C, Li S, Zheng Y, Wang Y, Cheng W, Huang Z. Botulinum Toxin Type A for refractory trigeminal neuralgia in older patients: a better therapeutic effect. J Pain Res. 2019;12:2177-2186. doi: 10.2147/JPR.S205467. PMID: 31410051; PMCID: MC6643497
20. Muñoz Lora VRM, Del Bel Cury AA, Jabbari B, Lacković Z. Botulinum Toxin Type A in Dental Medicine. J Dent Res. 2019;98(13):1450-1457. doi: 10.1177/0022034519875053. Epub 2019 Sep 18. PMID: 31533008
21. Moore D, Chong MS, Shetty A, Zakrzewska JM. A systematic review of rescue analgesic strategies in acute exacerbations of primary trigeminal neuralgia. Br J Anaesth. 2019 Aug;123(2):e385-e396. doi: 10.1016/j.bja.2019.05.026. Epub 2019 Jun 15. PMID: 31208761; PMCID: PMC6676170.
22. Sridharan K, Sivaramakrishnan G. Botulinum Toxin for Refractory Trigeminal Neuralgia: A Trial Sequential Analysis of Randomized Clinical Trials. J Neurosci Rural Pract.;9(1):3-4. doi: 10.4103/jnrp.jnr p_447_17. PMID: 29456335; PMCID: PMC5812155
23. Meng F, Peng K, Yang JP, Ji FH, Xia F, Meng XW. Botulinum toxin-A for the treatment of neuralgia: a systematic review and meta-analysis. J Pain Res. 2018 Oct 12;11:2343-2351. doi: 10.2147/ JPR.S168650. PMID: 30349359; PMCID: PMC6190 814
24. Castillo-Álvarez F, Hernando de la Bárcena I, Marzo-Sola ME. Botulinum toxin in trigeminal neuralgia. Med Clin. 2017;148(1):28-32. English, Spanish. doi: 10.1016/j.medcli.2016.07.032. Epub 2016 Oct 12. PMID: 27743594.
25. TURK Türk Börü Ü, Duman A, Bölük C, Coşkun Duman S, Taşdemir M. Botulinum toxin in the treatment of trigeminal neuralgia: 6-Month follow-up. Medicine (Baltimore). 2017;96(39):e8133. doi: 10.1097/MD.0000000000008133. PMID: 2895 3646; PMCID: PMC5626289.
26. Morra ME, Elgebaly A, Elmaraezy A, Khalil AM, Altibi AM, Vu TL, Mostafa MR, Huy NT, Hirayama K. Therapeutic efficacy and safety of Botulinum Toxin A Therapy in Trigeminal Neuralgia: a systematic review and meta-analysis of randomized controlled trials. J Headache Pain. 2016;17(1):63. doi: 10.118 6/s10194-016-0651-8. Epub 2016 Jul 5. PMID: 273 77706; PMCID: PMC4932020.
27. Oh HM, Chung ME. Botulinum Toxin for Neuropathic Pain: A Review of the Literature. Toxins (Basel). 2015;7(8):3127-54. doi: 10.3390/tox ins7083127. PMID: 26287242; PMCID: PMC4549742.
28. Hu Y, Guan X, Fan L, Li M, Liao Y, Nie Z, Jin L. Therapeutic efficacy and safety of botulinum toxin type A in trigeminal neuralgia: a systematic review. J Headache Pain. 2013;14(1):72. doi: 10.11 86/1129-2377-14-72. PMID: 23964790; PMCID: PMC3765392
29. Kaya DI, Ataoglu H. Botulinum toxin treatment of temporomandibular joint pain in patients with bruxism: A prospective and randomized clinical study. Niger J Clin Pract. 2021;24(3):412-417.
doi: 10.4103/njcp.njcp_251_20. PMID: 33723117.
30. La Fleur P, Adams A. Botulinum Toxin for Temporomandibular Disorders: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020 Feb 25. PMID: 33074614
31. Shandilya S, Mohanty S, Sharma P, Chaudhary Z, Kohli S, Kumar RD. Effect of Preoperative Intramuscular Injection of Botulinum Toxin A on Pain and Mouth Opening After Surgical Intervention in Temporomandibular Joint Ankylosis Cases: A Controlled Clinical Trial. J Oral Maxillofac Surg;78 (6):916-926. doi: 10.1016/j.joms.2020.02.011. Epub 2020 Feb 19. PMID: 32171600.
32. Thambar S, Kulkarni S, Armstrong S, Nikolarakos D. Botulinum toxin in the management of temporomandibular disorders: a systematic review. Br J Oral Maxillofac Surg. 2020;58(5):508-519. doi: 10.1016/j.bjoms.2020.02.007. Epub 2020 Mar 3. PMID: 32143934.
33. Machado D, Martimbianco ALC, Bussadori SK, Pacheco RL, Riera R, Santos EM. Botulinum Toxin Type A for Painful Temporomandibular Disorders: Systematic Review and Meta-Analysis. J Pain. 2020;21(3-4):281-293. doi: 10.1016/j.jpain.2 019.08.011. Epub 2019 Sep 9. PMID: 31513934.
34. Awan KH, Patil S, Alamir AWH, Maddur N, Arakeri G, Carrozzo M, Brennan PA. Botulinum toxin in the management of myofascial pain associated with temporomandibular dysfunction. J Oral Pathol Med.2019;48(3):192-200. doi: 10.1111/jop.12822. Epub 2019 Jan 25. PMID: 30604895.
35. Ghavimi MA, Yazdani J, Afzalimehr A, Ghoreyshizadeh A, Dehnad SV. Effect of injection of botulinum toxin on decreasing the symptoms and signs of masticatory muscles in patients with temporomandibular dysfunction. J Dent Res Dent Clin Dent Prospects. 2019 Spring;13(2):128-132. doi: 10.15171/joddd.2019.020. Epub 2019 Aug 14. PMID: 31592308; PMCID: PMC6773914
36. De la Torre Canales G, Câmara-Souza MB, do Amaral CF, Garcia RC, Manfredini D. Is there enough evidence to use botulinum toxin injections for bruxism management? A systematic literature review. Clin Oral Investig. 2017;21(3):727-734. doi: 10.1007/s00784-017-2092-4. Epub 2017 Mar 2. PMID: 28255752.
37. Thomas NJ, Aronovich S. Does Adjunctive Botulinum Toxin A Reduce Pain Scores When Combined With Temporomandibular Joint Arthroscopy for the Treatment of Concomitant Temporomandibular Joint Arthralgia and Myofascial Pain? J Oral Maxillofac Surg. 2017;75(12):2521-2528. doi: 10.1016/j.joms.2017.04.011. Epub 2017 Apr 19. PMID: 28500876.
38. Torres-Ferrus M, Gallardo VJ, Alpuente A, Pozo-Rosich P. Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA. J Headache Pain. 2020;21(1):88. doi: 10.1186/s101 94-020-01157-8. PMID: 32652924; PMCID: PMC7353810.
39. Bellon G, Venturin A, Masiero S, Del Felice A. Intra-articular botulinum toxin injection in complex regional pain syndrome: Case report and review of the literature. Toxicon. 2019;159:41-44. doi: 10.10 16/j.toxicon.2019.01.002. Epub 2019 Jan 17. PMID: 30660558.
40. Agostoni EC,Barbanti P, Calabresi P, Colombo B, Cortelli P, Frediani F, Geppetti P, Grazzi L, Leone M, Martelletti P, Pini LA, Prudenzano MP, Sarchielli P, Tedeschi G, Russo A; Italian chronic migraine group. Current and emerging evidence-based treatment options in chronic migraine: a narrative review. J Headache Pain. 2019;20(1):92. doi: 10.1186/s10194-019-1038-4. PMID: 31470791; PMCID: PMC6734211.
41. Kelli. AM. The minimum clinically significant difference in visual analogue scale pain score does not differ with severity of pain. Emerg Med J 2001; 18:205–7. 10.1136/emj.18.3.205.
42. Luvisetto S. Botulinum Toxin and Neuronal Regeneration after Traumatic Injury of Central and Peripheral Nervous System. Toxins (Basel). 2020;12 (7):434. doi: 10.3390/toxins12070434. PMID: 3263 0737; PMCID: PMC7404966
43. Herd CP, Tomlinson CL, Rick C, Scotton WJ, Edwards J, Ives NJ, Clarke CE, Sinclair AJ. Cochrane systematic review and meta-analysis of botulinum toxin for the prevention of migraine. BMJ Open. 2019;9(7):e027953. doi: 10.1136/bmjopen-2018-027953. PMID: 31315864; PMCID: PMC6661 560.
44. Herd CP, Tomlinson CL, Rick C, Scotton WJ, Edwards J, Ives NJ, Clarke CE, Sinclair AJ. Cochrane systematic review and meta-analysis of botulinum toxin for the prevention of migraine. BMJ Open. 2019;9(7):e027953. doi: 10.1136/bmjopen-2018-027953. PMID: 31315864; PMCID: PMC6661 560.
45. Freund B, Rao A. Efficacy of Botulinum Toxin in Tension-Type Headaches: A Systematic Review of the Literature. Pain Pract. 2019;19(5):541-551. doi: 10.1111/papr.12773. Epub 2019 Apr 22. PMID: 30742360.
46. Barad M, Sturgeon JA, Fish S, Dexter F, Mackey S, Flood PD. Response to BotulinumtoxinA in a migraine cohort with multiple comorbidities and widespread pain. Reg Anesth Pain Med. 2019; 44(6):660-668. doi: 10.1136/rapm-2018-100196. PMID: 31101743.
47. Mimeh H, Fenech Magrin AM, Myers S, Ghanem AM. A Critical Review of Botulinum Toxin Type A in the Prophylactic Treatment of Chronic Migraine in Adults. Aesthet Surg J. 2019;39(8):898-907. doi: 10.1093/asj/sjy224. PMID: 30184084.
48. Alpuente A, Gallardo VJ, Torres-Ferrus M, Alvarez-Sabin J, Pozo-Rosich P. Early efficacy and late gain in chronic and high-frequency episodic migraine with onabotulinumtoxinA. Eur J Neurol. 2019;26(12):1464-1470. doi: 10.1111/ene.14028. Epub 2019 Jul 18. PMID: 31220392.
49. Winner PK, Blumenfeld AM, Eross EJ, Orejudos AC, Mirjah DL, Adams AM, Brin MF. Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: Results of the COMPEL Study. Drug Saf. 2019;42(8):1013-1024. doi: 10.1007/s40264-019-00824-3. PMID: 31102144
50. Castrillo Sanz A, Morollón Sánchez-Mateos N, Simonet Hernández C, Fernández Rodríguez B, Cerdán Santacruz D, Mendoza Rodríguez A, Rodríguez Sanz MF, Tabernero García C, Guerrero Becerra P, Ferrero Ros M, Duate García-Luis J. Experience with botulinum toxin in chronic migraine. Neurologia. 2018;33(8):499-504. English.
51. Blumenfeld AM, Stark RJ, Freeman MC, Orejudos A, Manack Adams A. Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19(1):13. doi: 10.1186/s10194-018-0840-8. PMID: 29404713; PMCID: PMC5799088
52. Erdemoglu AK, Varlibas A. The long-term efficacy and safety of botulinum toxin in refractory chronic tension-type headache. J Headache Pain. 2007 Oct;8(5):294-300. doi: 10.1007/s10194-007-0414-7. Epub 2007 Oct 23. PMID: 17955170; PMCID: PMC3476152.
53. Mathew NT, Jaffri SF. A double-blind comparison of onabotulinumtoxina (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study. Headache 2009;49:1466–78. 10.1111/j.1526-4610.2009.01566.x
54. Venancio Rde A, Alencar FG Jr, Zamperini C. Botulinum toxin, lidocaine, and dry-needling injections in patients with myofascial pain and headaches. Cranio. 2009 Jan;27(1):46-53. doi: 10.1179/crn.2009.008. PMID: 19241799.
55. Jackson JL, Kuriyama A, Hayashino Y. Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis. JAMA. 2012; 307(16):1736-45. doi: 10.1001/jama.2012.505. PMID: 22535858.